A Phase I study of TMG-123, 7 days repeat administraiton

Placebo-controlled, double-blind, repeated oral dose, clinical pharmacology study of TMG-123 in patients with type 2 diabetes mellitus

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223650

Enrollment

Registered

2017-09-05

Start date

2017-09-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

investigational material(s) Generic name etc : TMG-123 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : 8

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: Subjects with type 1 diabetes mellitus or diabetes due to other specific mechanisms or diseases Subjects judged as not eligible by the investigator or sub-investigators for other reasons

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026